Mr. George Reznik reports

HEALTHCARE TECHNOLOGY COMPANY LIGHT AI ANNOUNCES ADVISORY BOARD TO AUGMENT BOARD OF DIRECTORS

Light AI Inc. has formed its advisory board. The advisory board has been designed to accelerate Light AI's goal of becoming a leader in the global AI health care market and will provide oversight and strategic guidance, advise on go-to-market strategies, and collaborate closely with the company's leadership team and board of directors.

The distinguished members of Light AI's advisory board include the following.

Yu Zhao

Mr. Zhao is the president of Bridging Consulting LLC, a boutique regulatory firm supporting AI (artificial intelligence) start-ups and medical device companies. With 16 years of leadership experience at Medtronic, including roles as director and interim vice-president of regulatory affairs, Mr. Zhao offers expert insights into navigating complex regulatory landscapes. Over the course of his career, Mr. Zhao and his teams have secured more than 150 U.S. Food and Drug Administration (FDA) approvals and clearances, spanning premarket approvals (PMAs), PMA supplements, investigational device exemptions, 510(k)s and de novos, for a wide range of devices -- from implantable devices to deep-learning algorithms.

Raymond Ng

Mr. Ng is a professor of computer science at the University of British Columbia and the director of the Data Science Institute. Mr. Ng is a recognized authority in machine learning and data science, contributing invaluable expertise to the advisory committee. He has published over 250 refereed articles on diverse topics related to data science. He is the Canada research chair on data science and analytics and an elected fellow of the Royal Society of Canada. For both 2022 and 2023, he was named one of the world's top 75 academic data science leaders by the MIT-based (Massachusetts Institute of Technology) CDO magazine.

Dr. David A. Talan

Dr. Talan is board certified in internal medicine, emergency medicine and infectious diseases and serves as professor of medicine in residence (emeritus) at UCLA and the University of Iowa. He has chaired the Olive View-UCLA Department of Emergency Medicine and is currently on the faculty at UCLA Ronald Reagan Medical Center. Dr. Talan's research focuses on acute infections, emergency-department-based surveillance and epidemiological research of emerging infections. He has numerous publications in prestigious journals, and his work has significantly influenced the management of infectious diseases.

David Bell

Mr. Bell is a public health physician and expert in infectious disease diagnostics. Formerly leading malaria diagnostics co-ordination at the WHO (World Health Organization), program head of malaria and acute febrile disease at the Foundation for Innovative New Diagnostics (FIND), and director of global health technologies at Intellectual Ventures Global Good Fund, he now consults in global health and biotechnology, driving impactful solutions in global health.

"We proudly welcome such experienced members to our advisory board," said Peter Whitehead, chief executive officer of Light AI. "These accomplished leaders bring a wealth of expertise that aligns with Light AI's commitment to drive technology advancements through the health care sector, and, together, we will accelerate Light AI's success and deliver transformative solutions to support the future of health care, globally."

The company's chief executive officer, Peter Whitehead, holds over two decades of experience in health care innovation and is the inventor of the VELscope, a market-leading oral cancer and oral disease imaging tool. VELscope was patented in 2000 and has been used in over 50 million oral health examinations by more than 20,000 dental practitioners in 23 countries.

Board of directors

The company also has an experienced board of directors with extensive medical health care industry, global business and financial capital markets expertise.

Steven Semmelmayer (chair)

Mr. Semmelmayer is a health care industry veteran with nearly four decades of experience under his belt. Mr. Semmelmayer has an impressive record as the former chief executive officer of Denmat Holdings, Discus Dental, Kerr Dental and LED Medical Diagnostics. His leadership and strategic expertise have shaped numerous organizations, making him a respected figure in the health care sector.

Emmanuel Blin

Mr. Blin has a wealth of experience in strategic planning, digital innovation and social impact in health care. Mr. Blin is the chief executive officer and founder of TC4A (Tech Care for All), a global digital health care platform revolutionizing care delivery. Previously, Mr. Blin was the chief strategy officer at Bristol Myers Squibb (BMS), where he managed commercial organizations across the globe in Europe, Asia and the United States for over 20 years. He has led the global launch and commercialization of several key brands, including Eliquis, Opdivo, Orencia, HIV and HCV (hepatitis C) products.

Mark Attanasio

Mr. Attanasio is the founder of Atta Elevators Corp. and the owner of Nocera Investment Corp., specializing in Canadian venture capital. His leadership credentials include serving as chief executive officer of Eight Capital and Dundee Capital Markets. Mr. Attanasio brings a deep understanding of investment strategies and corporate growth to the board, having spent 16 years in investment banking with a major Canadian financial institution. Mr. Attanasio holds his CPA/CA designation.

Hugh Cleland

Mr. Cleland is an accomplished leader in capital growth and business development. Mr. Cleland is the co-founder and chief executive officer of Roadmap Capital, a deep-technology venture capital investment platform that connects high-net-worth investors with disruptive technology companies in sectors such as semiconductors, cybersecurity, materials science and medical imaging. He holds a bachelor of arts from Harvard University and earned his CFA designation in 2001. Previously, he managed the Northern Rivers Innovation Fund, which won the Opportunistic Strategy Hedge Fund of the Year at the 2006 Canadian Investment Awards. Under his leadership, Roadmap Capital has invested over $250-million in venture-capital-stage companies, achieving notable exits such as the acquisitions of Tornado Spectral Systems and GEO Semiconductor. Mr. Cleland also serves on the boards of Perimeter Medical Imaging, Ubilite Inc., MMB, Corsa Security and Char Technologies.

About Light AI Inc.

Light AI is a health care company focused on developing artificial intelligence health diagnostic applications. Light AI is developing a technology platform that represents the next generation of patient management: It applies AI algorithms to smart phone images -- starting with images of streptococcus A -- to identify the disease in seconds. Its patented, app-based solution requires no swabs, lab tests or proprietary hardware of any kind; its hardware platform is the 4.5 billion smart phones that exist in the world today.

In pre-FDA validation studies, Light AI's algorithm demonstrated remarkable accuracy in differentiating between viral and bacterial pharyngitis, specifically targeting Group A streptococcus (GAS). The company's algorithm-generated pre-FDA results were in the range of the gold-standard swab culture currently used for diagnosing GAS, achieving a 96.57-per-cent accuracy rate and a negative predictive value (NPV) of 100 per cent, indicating its high reliability in confirming the absence of streptococcus A infection. Viral and GAS pharyngitis affects over 600 million people annually worldwide. If left untreated, GAS pharyngitis can lead to serious complications such as rheumatic heart disease (RHD), which imposes a global economic burden exceeding $1-trillion annually. Light AI's technology offers a significant advancement in the accurate and timely diagnosis of GAS pharyngitis, potentially reducing the incidence of RHD and its associated costs. Light AI's approach to applying AI to smart phone images can be expanded to other throat conditions as well as other areas of analysis, such as the human eye and skin. Light AI's vision is to combine the smart phone with AI in the cloud to create a digital clinical lab that provides quick and accessible diagnosis for countless conditions that today require expensive and time-consuming imaging or lab processes.

We seek Safe Harbor.